one more breath…
Join the conversation on our digital communities.
@letswinpc @loconte: @ShaalanBeg @Aiims1742 @mtmdphd @HCCvPDAC @PanCAN @MaenAbdelrahim @pashtoonkasi @NiuSanford @cancercommons @letswinpc This is in part inequity baked into Medicaid coverage. Cancer centers that don’t permit M’caid and m’caid obscenely low payment rates
@letswinpc @NiuSanford: @ShaalanBeg @Aiims1742 @mtmdphd @HCCvPDAC @PanCAN @MaenAbdelrahim @pashtoonkasi @cancercommons @letswinpc Front line per NCDB will exclude 2nd and 3rd line trials and probably post-op adjuvant studies too - so total % of PDAC patients enrolling on trials higher than 0.4% - but still overall single digits I would think.
@letswinpc @ShaalanBeg: Only 0.4% of people diagnosed w pancreatic cancer enrolled on a 'front line' clinical trial (analysis from the NCDB). While the overall clinical trial participation has increased over the years, this was not the case for those who are black or on medicaid. #pancchat #pancsm https://t.co/KJR70DECfd https://t.co/NAbTfTta73
An affiliate of
In partnership with